ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

DCOY vs JUNS // DIVIDEND YIELD & FCF PAYOUT SAFETY

Decoy Therapeutics Inc. (NASDAQ) VS. Jupiter Neurosciences Inc. (NASDAQ) • 15-METRIC TALLY: DCOY 2 — JUNS 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DCOY VS. JUNS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC DCOY JUNS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 80.60% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety ACTIVE 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 DCOY /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 34.1 32.2 +1.90 DCOY /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.9M $3.1M -$191.0K JUNS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR DCOY REV JUNS REV DCOY GROSS % JUNS GROSS % DCOY FCF JUNS FCF
FY 2025 $0 $21.8K — 80.6% -$4.8M -$5.4M
FY 2024 $0 $0 — — -$4.5M -$3.9M
FY 2023 $0 $0 — — -$12.8M -$481.0K
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DCOY // BETA —
JUNS // BETA —